These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 7794292)

  • 21. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nimodipine in the treatment of old age dementias.
    Ban TA; Morey L; Aguglia E; Azzarelli O; Balsano F; Marigliano V; Caglieris N; Sterlicchio M; Capurso A; Tomasi NA
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(4):525-51. PubMed ID: 2236581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nimodipine, a dihydropyridine-type calcium channel blocker, prevents alcoholic hepatitis caused by chronic intragastric ethanol exposure in the rat.
    Iimuro Y; Ikejima K; Rose ML; Bradford BU; Thurman RG
    Hepatology; 1996 Aug; 24(2):391-7. PubMed ID: 8690410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroprotective effect of dauricine in cortical neuron culture exposed to hypoxia and hypoglycemia: involvement of correcting perturbed calcium homeostasis.
    Li YH; Gong PL
    Can J Physiol Pharmacol; 2007 Jun; 85(6):621-7. PubMed ID: 17823624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global rating, symptoms, behavior, and cognitive performance as indicators of efficacy in clinical studies with nimodipine in elderly patients with cognitive impairment syndromes.
    Schmage N; Bergener M
    Int Psychogeriatr; 1992; 4 Suppl 1():89-99. PubMed ID: 1504290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From pharmacological promises to controlled clinical trials to meta-analysis and back: the case of nimodipine in cerebrovascular disorders.
    Di Mascio R; Marchioli R; Tognoni G
    Clin Trials Metaanal; 1994 Apr; 29(1):57-79. PubMed ID: 10150186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Drug evaluation of huperzine A in the treatment of senile memory disorders].
    Zhang RW; Tang XC; Han YY; Sang GW; Zhang YD; Ma YX; Zhang CL; Yang RM
    Zhongguo Yao Li Xue Bao; 1991 May; 12(3):250-2. PubMed ID: 1781288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical differentiation of primary degenerative and multi-infarct dementia: a critical review of the evidence. Part II: Pathological studies.
    Liston EH; La Rue A
    Biol Psychiatry; 1983 Dec; 18(12):1467-84. PubMed ID: 6661474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical aspects of nimodipine.
    Grobe-Einsler R
    Clin Neuropharmacol; 1993; 16 Suppl 1():S39-45. PubMed ID: 8519001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nimodipine: cognition, aging, and degeneration.
    de Jonge MC; Traber J
    Clin Neuropharmacol; 1993; 16 Suppl 1():S25-30. PubMed ID: 8518999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of nimodipine on mental deterioration in subjects with chronic cerebrovascular pathology].
    Canadè V; Catapano F; Muraca L; Cosentino A
    Minerva Med; 1991 Mar; 82(3):111-4. PubMed ID: 2006028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology of nimodipine. A review.
    Scriabine A; van den Kerckhoff W
    Ann N Y Acad Sci; 1988; 522():698-706. PubMed ID: 3288065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial.
    Pantoni L; del Ser T; Soglian AG; Amigoni S; Spadari G; Binelli D; Inzitari D
    Stroke; 2005 Mar; 36(3):619-24. PubMed ID: 15692125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Moving from the question of efficacy to the question of therapeutic relevance: an exploratory reanalysis of a controlled clinical study of 130 inpatients with dementia syndrome taking piracetam.
    Herrmann WM; Stephan K
    Int Psychogeriatr; 1992; 4(1):25-44. PubMed ID: 1391670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Alcoholic dementia and divalent ions: derangement of calcium-homeostasis].
    Tsuji M; Nakamura M; Tohara S; Nakajima T
    Arukoru Kenkyuto Yakubutsu Ison; 1991 Dec; 26(6):467-88. PubMed ID: 1785956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropharmacology of nimodipine: from single channels to behavior.
    Fanelli RJ; McCarthy RT; Chisholm J
    Ann N Y Acad Sci; 1994 Dec; 747():336-50. PubMed ID: 7847682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Down-regulation of free intracellular calcium in dissociated brain cells of aged mice and rats.
    Hartmann H; Eckert A; Velbinger K; Rewsin M; Müller WE
    Life Sci; 1996; 59(5-6):435-49. PubMed ID: 8761332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Piracetam, nimodipine and tacrine in the pharmacologic treatment of dementia: bibliographic review].
    Ojer Tsakiridu D; Dosantos Hernández JO; Larrabe Medina J; Sánchez Casado JI; Sologuren Echenagusia A
    Aten Primaria; 1996 Sep; 18(5):257-60, 262-4. PubMed ID: 8936720
    [No Abstract]   [Full Text] [Related]  

  • 39. Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study.
    Maina G; Fiori L; Torta R; Fagiani MB; Ravizza L; Bonavita E; Ghiazza B; Teruzzi F; Zagnoni PG; Ferrario E
    Neuropsychobiology; 1989; 21(3):141-5. PubMed ID: 2693996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can nimodipine affect progression of motor neuron disease? A double-blind pilot study.
    Ziv I; Achiron A; Djaldetti R; Abraham M; Melamed E
    Clin Neuropharmacol; 1994 Oct; 17(5):423-8. PubMed ID: 9316691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.